Pune, Jan. 21, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Sleep Apnea Devices market size was valued at USD 5.25 billion in 2023 and is expected to reach USD 9.43 billion by 2032, growing ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

In a report released on January 31, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target ...

ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway Pressure (CPAP) device designed ...

(RTTNews) - Resmed Inc (RMD) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The company's earnings totaled $344.6 million, or $2.34 per share.